Need help now? Free crisis lines and helplines, worldwide — chapter 02 →
0 results for

Coming Off Medication Safely — Tapering & Deprescribing

Category 7 of 20 in chapter 17, The Research Behind It, of Notbroken's Free Metabolic & Mental Health Help Directory: 13 listings, each carefully picked (listed, not endorsed). All 280 listings in The Research Behind It · Open the full directory of 2299 listings.
13
Listings
7 / 20
Category
17 / 18
Chapter
Latest Edition Always download the most up-to-date version, free, at notbroken.io
Know someone who could benefit? Share this guide with them.
Free to use · No account needed
Navigation
Contents
17
The Research Behind It — Free Papers on Chronic Disease and What the Evidence Shows
THE EVIDENCE
THE EVIDENCE

The Research Behind It — Free Papers on Chronic Disease and What the Evidence Shows

Why would a support group, a walking club, a low-carb book or an online CBT course help — and what drives chronic illness in the first place? This chapter gathers the research behind each part of the directory, and the research on causes: metabolic therapies, the nutrients in food, plastics and pollution, stress and trauma, the microbiome, and damp and mould. That is 280 studies, reviews and clinical guidelines, every one free to read and download in full, permanently and without a login. Most are kept in PubMed Central, the US National Library of Medicine's public archive; the rest are open access at the publisher, or free guidance from the World Health Organization and NICE. Each entry says what was found, why it matters here — which listings it backs up, or what it explains about chronic disease — and how strong the evidence is: strong (systematic reviews and guidelines with consistent findings), moderate (smaller or lower-certainty reviews, single large trials and large cohort studies) or early (pilot, cross-sectional and laboratory studies — promising, not proof). Studies that follow people over time show links, not proof of cause, and the entries say so. Where a study was funded by a company, or its authors run a listed programme, the note says so; where a listed book or service was not itself tested, the entry says it backs the approach rather than the product. Research moves on, so read these as good reasons to try something, not guarantees — and talk to your own clinician before changing a treatment or a medicine. Every paper was checked at least twice: by the researcher who chose it and again, independently, against its abstract and full text (the first 186 a third time); its public record was checked for corrections, retractions and expressions of concern (none is retracted), every number was looked up in the full text, and every link was opened in a browser.

Coming Off Medication Safely — Tapering & Deprescribing

Before you start: Never stop or reduce a prescribed medicine on your own: some medicines cause withdrawal effects or a relapse if they are stopped or cut down too quickly. Use these resources to plan it with your prescriber.

Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults — NICE 2022

National clinical guideline (England) based on evidence reviews by the National Guideline Centre; covers opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants. Moderate evidence. NICE guideline NG215, 20 April 2022. Free to read on the NICE website. Note: NICE found the evidence comparing tapering speeds inconclusive, so much of the advice on how to withdraw rests on committee experience; written for adults in England.
What It Found
NICE's guideline on withdrawing opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants. Prescribers should not stop them abruptly except in exceptional circumstances such as serious side effects, should reach agreement by shared decision-making, make sure the planned rate of reduction is acceptable to the person and reviewed regularly, and explain that withdrawal can be difficult and may take several months or more. It suggests offering details of peer support.
Why It Matters Here
Backs up the tapering and deprescribing resources in chapter 06, especially UK ones such as Mind's coming-off-medication guide, LEAP for Prescribed Drug Dependence and the Beyond Pills Alliance, by setting out agreed, gradual withdrawal with access to peer support as recommended practice. Most relevant in the UK.
National clinical guideline (England) based on evidence reviews by the National Guideline Centre; covers opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants. Moderate evidence. NICE guideline NG215, 20 April 2022. Free to read on the NICE website. Note: NICE found the evidence comparing tapering speeds inconclusive, so much of the advice on how to withdraw rests on committee experience; written for adults in England.

A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? — Davies & Read, Addict Behav 2019

Systematic review — 24 studies of mixed design and size (including online surveys, observational studies and trials); weighted averages, no formal meta-analysis. Moderate evidence. Addict Behav 2019;97:111–121. Free full text at the publisher — open access, CC BY-NC-ND 4.0. Note: Relied heavily on self-selected online surveys and drew published critiques; a 2024 meta-analysis (Henssler et al.) estimated a lower rate: 31%, or about 15% allowing for placebo effects.
What It Found
Reviewed 24 studies to test UK and US guideline statements that antidepressant withdrawal is 'self-limiting', typically resolving within one to two weeks. In 14 studies, 27% to 86% of people had withdrawal effects (weighted average 56%); in four large studies a weighted average of 46% of those affected chose the most severe rating offered; seven of ten studies on duration found a significant proportion affected for more than two weeks, and several months was not uncommon.
Why It Matters Here
Backs up the antidepressant withdrawal resources in chapter 06 (the Tapering Strip, Outro Health, Inner Compass Initiative, Surviving Antidepressants, LEAP and Mind's guide) by showing withdrawal can be common and sometimes severe or long-lasting; it did not test any tapering method.
Systematic review — 24 studies of mixed design and size (including online surveys, observational studies and trials); weighted averages, no formal meta-analysis. Moderate evidence. Addict Behav 2019;97:111–121. Free full text at the publisher — open access, CC BY-NC-ND 4.0. Note: Relied heavily on self-selected online surveys and drew published critiques; a 2024 meta-analysis (Henssler et al.) estimated a lower rate: 31%, or about 15% allowing for placebo effects.

Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis — Henssler et al., Lancet Psychiatry 2024

Systematic review and meta-analysis — 79 studies (44 randomised trials, 35 observational), 21,002 people. Moderate evidence. Lancet Psychiatry 2024;11(7):526–535. Free full text at the publisher — open access, CC BY 4.0. Note: Heterogeneity was substantial, studies defined and measured symptoms differently and many were small; it drew critical letters, including from Read and Davies, and an erratum in 2024.
What It Found
Pooled 79 studies (21,002 people) in which an antidepressant or placebo was stopped. At least one discontinuation symptom followed stopping an antidepressant in 31% (95% CI 27–35%) versus 17% after placebo; severe symptoms in 2.8% versus 0.6%. Allowing for non-specific effects seen with placebo, the authors estimate about 15% (one in six to seven). Desvenlafaxine, venlafaxine, imipramine, escitalopram and paroxetine were linked to more frequent or severe symptoms.
Why It Matters Here
Backs up the antidepressant tapering listings in chapter 06 with a large, recent estimate of how often discontinuation symptoms occur, and helps readers weigh it against higher survey-based figures such as Davies and Read's.
Systematic review and meta-analysis — 79 studies (44 randomised trials, 35 observational), 21,002 people. Moderate evidence. Lancet Psychiatry 2024;11(7):526–535. Free full text at the publisher — open access, CC BY 4.0. Note: Heterogeneity was substantial, studies defined and measured symptoms differently and many were small; it drew critical letters, including from Read and Davies, and an erratum in 2024.

Internet and Telephone Support for Discontinuing Long-Term Antidepressants: The REDUCE Cluster Randomized Trial — Kendrick et al., JAMA Netw Open 2024

Cluster randomised trial — 131 UK general practices, 330 long-term antidepressant users. Moderate evidence. JAMA Netw Open 2024;7(6):e2418383. DOI 10.1001/jamanetworkopen.2024.18383. Free full text in PubMed Central (PMC11197448) — open access, CC BY. Note: Only 4.9% of patients invited took part (a selected, low-risk group), and the extra support did not increase the number who stopped.
What It Found
In 131 UK general practices, 330 adults on long-term antidepressants who were well, at low risk of relapse and wanted to try stopping had a GP review; practices randomised to the intervention also offered online self-management and telephone support. With the extra support, depression scores at six months were no worse (PHQ-9 difference −1.1, 95% CI −2.1 to −0.1) and withdrawal symptoms slightly less severe; similar proportions stopped (45.5% vs 41.9%).
Why It Matters Here
Backs up the clinician-guided approach to reviewing long-term antidepressants offered by services such as Outro Health in chapter 06 (Outro itself was not tested); most relevant to people who are well and want to discuss stopping with their GP.
Cluster randomised trial — 131 UK general practices, 330 long-term antidepressant users. Moderate evidence. JAMA Netw Open 2024;7(6):e2418383. DOI 10.1001/jamanetworkopen.2024.18383. Free full text in PubMed Central (PMC11197448) — open access, CC BY. Note: Only 4.9% of patients invited took part (a selected, low-risk group), and the extra support did not increase the number who stopped.

Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study — Groot & van Os, Ther Adv Psychopharmacol 2021

Retrospective questionnaire cohort — 824 people who used tapering strips to try to stop an antidepressant. Early evidence. Ther Adv Psychopharmacol 2021;11:20451253211039327. DOI 10.1177/20451253211039327. Free full text in PubMed Central (PMC8404667) — open access, CC BY 4.0. Note: No comparison group, a 59% response rate and self-reported results; one author helped develop the strips, and the declared conflicts include a grant from the pharmacy that makes them.
What It Found
Surveyed people whose doctors had prescribed tapering strips (rolls of daily pouches, each the same as or slightly lower than the one before). Of 824 who wanted to stop an antidepressant (71% had tried to stop without strips at least once; 66% were on venlafaxine or paroxetine), 72% reported stopping, over a median of 56 days. Median recalled withdrawal severity was 3 with the strips versus 6 in attempts without them.
Why It Matters Here
Backs up the Tapering Strip listing in chapter 06 directly, and the gradual, hyperbolic approach described by Inner Compass Initiative and Surviving Antidepressants; most relevant to people who have struggled to stop before.
Retrospective questionnaire cohort — 824 people who used tapering strips to try to stop an antidepressant. Early evidence. Ther Adv Psychopharmacol 2021;11:20451253211039327. DOI 10.1177/20451253211039327. Free full text in PubMed Central (PMC8404667) — open access, CC BY 4.0. Note: No comparison group, a 59% response rate and self-reported results; one author helped develop the strips, and the declared conflicts include a grant from the pharmacy that makes them.

Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline — Pottie et al., Can Fam Physician 2018

Evidence-based clinical practice guideline (GRADE) with a systematic review of benzodiazepine and Z-drug deprescribing trials for insomnia. Moderate evidence. Can Fam Physician 2018;64(5):339–351. Free full text in PubMed Central (PMC5951648). Note: The evidence was rated low quality, and it covers insomnia only, not benzodiazepines taken for anxiety or other conditions.
What It Found
This deprescribing.org guideline recommends offering a slow taper to adults aged 65 or over who take benzodiazepines or Z-drugs for insomnia, whatever the duration of use (strong recommendation, low-quality evidence), and suggests the same for adults aged 18 to 64 who have used them for over four weeks (weak recommendation). Its review found tapering improved stopping rates over usual care without serious harms; it advises involving patients in the tapering plan.
Why It Matters Here
Backs up deprescribing.org and the Canadian Deprescribing Network in chapter 06, the slow-tapering approach the Benzodiazepine Information Coalition promotes, and the CBT-I programmes and sleep books in chapters 10 and 11, as the guideline pairs tapering with behavioural sleep advice.
Evidence-based clinical practice guideline (GRADE) with a systematic review of benzodiazepine and Z-drug deprescribing trials for insomnia. Moderate evidence. Can Fam Physician 2018;64(5):339–351. Free full text in PubMed Central (PMC5951648). Note: The evidence was rated low quality, and it covers insomnia only, not benzodiazepines taken for anxiety or other conditions.

Brief interventions targeting long-term benzodiazepine and Z-drug use in primary care: a systematic review and meta-analysis — Lynch et al., Addiction 2020

Systematic review and meta-analysis — 8 randomised trials, 2,071 patients. Moderate evidence. Addiction 2020;115(9):1618–1639. DOI 10.1111/add.14981. Free full text in PubMed Central (PMC7891570) — open access, CC BY-NC 4.0. Note: Only two of the eight trials were at low risk of bias in most areas, results varied between trials (I² 55%) and few included Z-drug users.
What It Found
Pooled 8 randomised trials (2,071 patients) of brief primary-care interventions for people taking benzodiazepines or Z-drugs for three months or more, mostly letters signed by the prescriber or a pharmacist, sometimes with a booklet, or a short consultation with a GP, pharmacist or nurse. Stopping was about 2.7 times as likely as with usual care at six months (RR 2.73, 95% CI 1.84–4.06) and about 3.4 times as likely at 12 months (2 trials).
Why It Matters Here
Backs up deprescribing.org, the Canadian Deprescribing Network and the Benzodiazepine Information Coalition in chapter 06: clear information and a prompt from a trusted clinician can help people come off sleeping pills and tranquillisers.
Systematic review and meta-analysis — 8 randomised trials, 2,071 patients. Moderate evidence. Addiction 2020;115(9):1618–1639. DOI 10.1111/add.14981. Free full text in PubMed Central (PMC7891570) — open access, CC BY-NC 4.0. Note: Only two of the eight trials were at low risk of bias in most areas, results varied between trials (I² 55%) and few included Z-drug users.

Effect of a Pharmacist-Led Educational Intervention on Inappropriate Medication Prescriptions in Older Adults: The D-PRESCRIBE Randomized Clinical Trial — Martin et al., JAMA 2018

Cluster randomised trial — 69 community pharmacies, 489 adults aged 65 or over. Moderate evidence. JAMA 2018;320(18):1889–1898. DOI 10.1001/jama.2018.16131. Free full text in PubMed Central (PMC6248132). Note: One Canadian province and six months' follow-up; too few people on antihistamines to analyse.
What It Found
489 Quebec adults aged 65+ on a potentially inappropriate medicine (sedative-hypnotics, glyburide, NSAIDs or older antihistamines) took part; in intervention pharmacies they got a deprescribing brochure and their doctor a pharmacist's advice. At six months 43% had stopped filling it vs 12% with usual care (risk difference 31%, 95% CI 23–38%); sedative-hypnotics 43% vs 9%. No adverse events needed hospital care; 38% of those tapering a sedative reported withdrawal symptoms.
Why It Matters Here
Backs up the Canadian Deprescribing Network and deprescribing.org in chapter 06, which offer patient deprescribing brochures of the kind tested here; most relevant to older adults on several medicines and to their carers.
Cluster randomised trial — 69 community pharmacies, 489 adults aged 65 or over. Moderate evidence. JAMA 2018;320(18):1889–1898. DOI 10.1001/jama.2018.16131. Free full text in PubMed Central (PMC6248132). Note: One Canadian province and six months' follow-up; too few people on antihistamines to analyse.

Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline — Farrell et al., Can Fam Physician 2017

Evidence-based clinical practice guideline (GRADE) with a systematic review of PPI deprescribing trials. Moderate evidence. Can Fam Physician 2017;63(5):354–364. Free full text in PubMed Central (PMC5429051). Note: Does not apply to people with Barrett's oesophagus, severe oesophagitis or a history of bleeding ulcers; the evidence dates from 2017.
What It Found
Guideline from the deprescribing.org team, built with GRADE methods, a systematic review of trials of reducing or stopping proton pump inhibitors and reviews of harms of long-term use. It recommends that adults who have taken a PPI for at least four weeks for heartburn, mild-to-moderate reflux or oesophagitis, and whose symptoms have settled, be offered a lower dose, use only when needed, or stopping.
Why It Matters Here
Backs up deprescribing.org and the Canadian Deprescribing Network in chapter 06, and gives useful background to readers of chapter 15's gastroenterology listings who take long-term reflux medicine.
Evidence-based clinical practice guideline (GRADE) with a systematic review of PPI deprescribing trials. Moderate evidence. Can Fam Physician 2017;63(5):354–364. Free full text in PubMed Central (PMC5429051). Note: Does not apply to people with Barrett's oesophagus, severe oesophagitis or a history of bleeding ulcers; the evidence dates from 2017.

Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline — Bjerre et al., Can Fam Physician 2018

Evidence-based clinical practice guideline (GRADE) drawing on a Cochrane review of withdrawal trials in dementia and a systematic review for insomnia. Moderate evidence. Can Fam Physician 2018;64(1):17–27. Free full text in PubMed Central (PMC5962971). Note: Covers dementia-related behaviour and insomnia only, not schizophrenia or bipolar disorder, where stopping carries different risks.
What It Found
Guideline from the deprescribing.org team, built with GRADE methods, a Cochrane review of antipsychotic withdrawal trials in dementia and a systematic review for insomnia. It recommends tapering and stopping antipsychotics in adults treated for at least three months for behavioural and psychological symptoms of dementia whose symptoms have settled or not responded, and in adults taking them for insomnia, with patients and carers involved in planning the taper.
Why It Matters Here
Backs up deprescribing.org and the Canadian Deprescribing Network in chapter 06, and the dementia support organisations in chapter 06 whose members and carers often face questions about antipsychotics.
Evidence-based clinical practice guideline (GRADE) drawing on a Cochrane review of withdrawal trials in dementia and a systematic review for insomnia. Moderate evidence. Can Fam Physician 2018;64(1):17–27. Free full text in PubMed Central (PMC5962971). Note: Covers dementia-related behaviour and insomnia only, not schizophrenia or bipolar disorder, where stopping carries different risks.

CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 — Dowell et al., MMWR Recomm Rep 2022

National clinical practice guideline (12 recommendations) informed by systematic reviews. Moderate evidence. MMWR Recomm Rep 2022;71(No. RR-3):1–95. DOI 10.15585/mmwr.rr7103a1. Free full text in PubMed Central (PMC9639433) — public domain. Note: Written for US clinicians; its tapering advice rests mainly on lower-certainty evidence and clinical experience.
What It Found
The US national guideline on opioids for pain (not for sickle cell disease, cancer or end-of-life care). It notes that rigid use of dose thresholds, and rapid tapers or abrupt stops without working with patients, have contributed to harms including serious withdrawal, worse pain, psychological distress, overdose and suicidal thoughts and behaviour. Unless there is a life-threatening issue, it advises against stopping opioids abruptly or rapidly reducing higher doses.
Why It Matters Here
Backs up the case made by chapter 06's deprescribing groups for slow, agreed and supported reductions, and the non-drug pain approaches in chapters 10 and 13 that the guideline encourages.
National clinical practice guideline (12 recommendations) informed by systematic reviews. Moderate evidence. MMWR Recomm Rep 2022;71(No. RR-3):1–95. DOI 10.15585/mmwr.rr7103a1. Free full text in PubMed Central (PMC9639433) — public domain. Note: Written for US clinicians; its tapering advice rests mainly on lower-certainty evidence and clinical experience.

Efficacy of interventions to reduce long term opioid treatment for chronic non-cancer pain: systematic review and meta-analysis — Avery et al., BMJ 2022

Systematic review and meta-analysis — 36 studies (27 randomised trials) kept after 130 were excluded for critical risk of bias. Moderate evidence. BMJ 2022;377:e066375. DOI 10.1136/bmj-2021-066375. Free full text in PubMed Central (PMC8977989) — open access, CC BY-NC 4.0. Note: Little evidence on possible harms such as overdose, which the authors call a particular concern; certainty was low or very low for 41 of 44 outcomes.
What It Found
Reviewed ways to help people on long-term opioids for chronic non-cancer pain reduce their use; 130 of 166 eligible studies were excluded for critical risk of bias. Pain self-management programmes probably lowered daily opioid dose (by about 14 mg oral morphine equivalent; 5 studies, 428 people; moderate certainty) and might moderately ease pain (low certainty); prescriber-focused interventions gave smaller dose reductions but made stopping somewhat more likely.
Why It Matters Here
Backs up the opioid side of chapter 06's deprescribing networks, and the pain self-management approach behind the courses, books and psychological therapies in chapters 05, 10 and 13 (those named listings were not tested themselves).
Systematic review and meta-analysis — 36 studies (27 randomised trials) kept after 130 were excluded for critical risk of bias. Moderate evidence. BMJ 2022;377:e066375. DOI 10.1136/bmj-2021-066375. Free full text in PubMed Central (PMC8977989) — open access, CC BY-NC 4.0. Note: Little evidence on possible harms such as overdose, which the authors call a particular concern; certainty was low or very low for 41 of 44 outcomes.

Association of Dose Tapering With Overdose or Mental Health Crisis Among Patients Prescribed Long-term Opioids — Agnoli et al., JAMA 2021

Retrospective cohort study — 113,618 US patients on stable, higher-dose long-term opioids (insurance claims, 2008–2019). Moderate evidence. JAMA 2021;326(5):411–419. DOI 10.1001/jama.2021.11013. Free full text in PubMed Central (PMC8335575). Note: Observational, so association not cause. Corrected in 2022 for coding errors (smaller but still significant effects); the PMC copy shows the original figures with the correction linked.
What It Found
Followed 113,618 US patients on stable, higher-dose long-term opioids. After a 2022 correction for coding errors, periods after a dose taper were still linked to more overdose or withdrawal events (adjusted incidence rate ratio 1.28, 95% CI 1.15–1.43) and more mental health crises (1.74, 1.50–2.01) than periods without tapering; the errors had inflated the original figures (1.68 and 2.28).
Why It Matters Here
Backs up chapter 06's message that reducing long-term opioids can carry real risks and should be done with care, monitoring and support; most relevant to people on long-term pain medicines and their families.
Retrospective cohort study — 113,618 US patients on stable, higher-dose long-term opioids (insurance claims, 2008–2019). Moderate evidence. JAMA 2021;326(5):411–419. DOI 10.1001/jama.2021.11013. Free full text in PubMed Central (PMC8335575). Note: Observational, so association not cause. Corrected in 2022 for coding errors (smaller but still significant effects); the PMC copy shows the original figures with the correction linked.
Important Disclaimer
This directory is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making changes to your medication regimen or starting any new therapy.

This document does not guarantee the legitimacy, quality, or suitability of any business, organization, or practitioner listed within. The inclusion of any listing does not constitute an endorsement, recommendation, or verification of credentials. All organizations listed are independent entities over which the creators of this directory have no control or oversight.

This directory is intended to be used as a starting point and reference for the reader to conduct their own research, exercise their own judgment, and apply their own discretion before engaging with any listed organization or professional. Readers are strongly encouraged to independently verify credentials, read reviews, check licensing, and confirm current pricing and availability directly with each organization before committing to any services.

Costs, availability, contact details, and services may change at any time without notice. Information was accurate to the best of our knowledge at the time of publication.

About Notbroken.io: this directory and the accompanying Breathe, Calm, Sleep, Move, Eat, Track and Build tools were created by Nathan Leary, who runs and updates them. How each tool works, its safety notes, the privacy policy and terms of use are at notbroken.io/about, notbroken.io/privacy and notbroken.io/terms. The tools are general wellness aids, not medical devices, and Track is a personal journal that never gives medication advice.

If you are in crisis: Please contact your local emergency services immediately, or reach out to one of the following helplines:

International: Chapter 02 of this directory lists free helplines by situation and country; elsewhere use Find A Helpline — findahelpline.com
United States: 988 Suicide & Crisis Lifeline (call or text 988) • Crisis Text Line (text HOME to 741741)
United Kingdom: Samaritans — 116 123 (free, 24/7)
Canada: Talk Suicide Canada — 988 (call or text, 24/7)
Australia: Lifeline — 13 11 14 (24/7) • Beyond Blue — 1300 22 4636
New Zealand: Need to Talk? — 1737 (free, 24/7)
Europe: European Emergency Number — 112
India: iCall — 9152987821 • Vandrevala Foundation — 1860 2662 345
Singapore: Samaritans of Singapore — 1-767 (24/7)
Japan: TELL Lifeline — 03-5774-0992

No matches found

Nothing matched . Try broadening your search — remove a filter, use a single keyword, describe what you need in a sentence, or browse by a condition, a place, or a type of support.

Suggest a resource